Combining these data together, we first identified JAK2/STAT3/CCND2 signaling as a resistance mechanism of CSCs for persistent growth after RT, and these findings suggest that this pathway can serve as a predictive biomarker and prime target to improve outcomes in CRC patients. The gene discussed is STAT3; the disease is colorectal carcinoma.